Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | STK3 | Q13188 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.51 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383216 | 0.84 | ABL1 (0.48) | ABL1NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL2382404 | 0.83 | NPC1 (0.60) | ROCK2RPS6KB1ROCK1SGK2NPC1 | |
| SCHEMBL2564063 | 0.79 | NPC1 (0.68) | ROCK2RPS6KB1ROCK1SGK2NPC1 | |
| SCHEMBL2380312 | 0.77 | CDK7 (0.45) | NPC1RAB9AJAK2KCNK3KCNK9 | |
| SCHEMBL2380902 | 0.75 | KDR (0.50) | ROCK2RPS6KB1ROCK1AURKACSF1R | |
| SCHEMBL2381767 | 0.74 | KCNK3 (0.47) | NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL2380306 | 0.74 | MAPK14 (0.49) | ABL1NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL2213049 | 0.73 | PIK3CD (0.70) | ABL1NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL14639945 | 0.73 | KCNK3 (0.40) | RPS6KB1AURKAAURKBNPC1RAB9A | |
| SCHEMBL29291558 | 0.73 | FLT3 (0.67) | ABL1ROCK2RPS6KB1ROCK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | ABL1 5/4885ROCK2 1532/4885RPS6KB1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.